2018 Prescription Drug Affordability Initiative
Our 2018 Prescription Drug Affordability Initiative proposes the following:
- TRANSPARENCY: Requiring prescription drug corporations to notify the public about expensive new drugs and large price increases for older drugs, and to justify those pricing decisions.
- REASONABLE RATES: Creating a Maryland Prescription Drug Cost Review Commission in Maryland to examine the evidence and establish acceptable costs for drugs.
- FAIRNESS: Preventing commercial managers of prescription drug plans from restricting what pharmacists can tell consumers about lower-cost drug options, as they sometimes do today.
Learn more and join our campaign today!
